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UTILIZATION REVIEW OF SSRI THERAPY AT
A MENTAL HEALTH MANAGED CARE
ORGANIZATION.
Conner TM, Rascati KL, Crawford KM
University of Texas at Austin, Austin, TX, USA
In an era of cost containment, psychiatric drug formular-
ies often limit choice of first-line selective serotonin re-
uptake inhibitors (SSRI) in the treatment of depression.
OBJECTIVES: Most patients in this study belong to one
of three managed care systems with varying drug formu-
laries. The purpose of this study was to describe treat-
ment events and utilization of services by patients with
depression initially prescribed one of three SSRIs in a
"treatment as usual" setting.
METHODS: Patients with major depression were identi-
fied in the organization database. Retrospective chart re-
views determined patient demographics, frequency of ad-
verse events, attrition rate, and utilization of services over
a six-month period following initiation of therapy.
RESULTS: One-hundred forty charts were reviewed. SSRIs
were equally prescribed. The mean age of patients was
39.5, (sd = 14.1). Approximately 38% were Hispanic.
Approximately 41 % had prior SSRI therapy. Prescribers
tended to follow restricted formularies but showed no
preference with an open formulary. Chi-square analyses
revealed that among the SSRIs, there was no difference in
attrition or in reports that patients had at least one ad-
verse effect. On average, patients received 2.3 prescriber
visits during the initial six months of therapy, with no
significant difference by SSRI.
CONCLUSIONS: Preliminary evidence suggests no dif-
ference in the number of outpatient prescriber visits, at-
trition rates, or reports of at least one adverse effect
among the three SSRIs. Further analysis will examine fre-
quency of patients who switched from initial SSRI to an-
other antidepressant. The results of this study are limited
by small sample size, non-randomization of patients, and
data derived from documentation in medical records. Fu-
ture research will prospectively measure symptomatology
of depression, along with utilization of services and treat-
ment events.
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TEXAS MEDICATION ALGORITHM PROJECT:
FEASIBILITY STUDY OF IMPLEMENTING
MEDICATION ALGORITHMS IN THE PUBLIC
MENTAL HEALTH SECTOR
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OBJECTIVE: The aim of this study was to determine the
feasibility and suitability of implementing consensually
Abstracts
derived, evidence based, medication algorithms in the
care of patients treated in the public mental health sector.
METHODS: Each of 40 physicians at 16 sites treated 5-
15 patients for up to 4 months with one of the algorithms
(schizophrenia [SCZj, bipolar disorder [BPDj, or major
depressive disorder [MDDj). Process measures included
visit frequency, staff time, algorithm stages used, time on
treatment stage, and medications used. Outcome mea-
sures included the Brief Psychiatric Rating Scale (BPRS),
Inventory of Depressive Symptoms (IDS), Clinical Global
Impression (CGI), and the Multnomah Community Abili-
ties Scale (MCAS).
RESULTS: 222 patients entered the study. Survival rate
at 90 days was 75%. Physician time was approximately
40 minutes at the initial visit and 30 minutes at follow-up
visits; visits were approximately 3 weeks apart. 52% of
patients with SCZ and 55% of patients with BPD had
>30% decrease in BPRS score. 38% of patients with
MDD had >50% decrease in IDS score. All patient
groups except outpatient SCZ had significant improve-
ment on the MCAS. Physician satisfaction was high with
nearly 80% of the physicians stating that they would con-
tinue using the algorithms.
CONCLUSIONS: Medication algorithms were imple-
mented in the population and in general were associated
with good improvement in patient symptoms and func-
tion. Major obstacles to widespread implementation are
adequate staffing, staff support, and availability of cer-
tain medications. Clinical and economic impact of the al-
gorithms are currently being evaluated in a comparative
study.
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MEASURE MIGRAINE-RELATED PRODUCTIVITY
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Migraine headache is a severe and debilitating disease
that is estimated to affect 4 out of 100 Americans. The
nature of migraine attacks and the variability in their oc-
currence have substantial economic implications.
OBJECTIVE: The purpose of this project is to develop a
multi-item, task-based instrument to measure the impact
of migraine on several domains. The domains include
workplace productivity, housekeeping, and impact on lei-
sure activities.
METHODS: An extensive review of the literature was
performed to determine methods of assessing migraine-
related productivity. Current instruments used in the
measurement of disease-related productivity were re-
viewed for content. Focus groups were held to determine
important productivity-related issues to migraineurs. The
groups consisted of migraineurs (n = 12) recruited by a
research organization and screened with an instrument
